We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Test Could Detect Elusive Neuro Disorder Using Tiny Drop of Spinal Fluid

By LabMedica International staff writers
Posted on 08 Jul 2024
Print article
Image: A brain scan showing the presence of progressive supranuclear palsy in the area circled in red (Photo courtesy of UCSF)
Image: A brain scan showing the presence of progressive supranuclear palsy in the area circled in red (Photo courtesy of UCSF)

Progressive supranuclear palsy (PSP) is a severe neurological disorder classified under frontotemporal dementia (FTD) that impairs cognition, movement, and behavior. Thought to be caused by an accumulation of tau proteins that damage and kill cells, PSP presents symptoms such as poor balance with frequent backward falls and difficulties moving the eyes vertically. Often misdiagnosed as Parkinson’s disease, PSP progresses more rapidly and does not respond to Parkinson’s treatments. Most individuals with PSP pass away approximately seven years after symptoms begin, and frequently, the disease is only identified posthumously during an autopsy. Unlike Alzheimer’s, there are no tau scans, blood tests, or MRIs that can conclusively diagnose PSP, a fact that has hampered the development of treatments. Now, the discovery of a unique pattern of proteins in the spinal fluid of patients could lead to earlier diagnosis and the development of new treatments for PSP.

In a study published in Neurology on July 3, researchers at the UCSF Department of Neurology (San Francisco, CA, USA) discovered a unique protein pattern in the spinal fluid of PSP patients. This finding was achieved using a novel high-throughput technology capable of analyzing thousands of proteins from just a small fluid sample. The researchers are optimistic that these protein biomarkers might lead to a diagnostic test and therapies aimed at halting the disease's deadly progression. Previous studies have noted the potential of various non-specific neurodegeneration biomarkers in PSP, though they have shown limited sensitivity and specificity, especially in the early stages of the disease. In this latest research, protein biomarkers were quantified using high-throughput technology, which utilizes molecules that bind selectively and specifically to proteins.

The study involved 136 participants, averaging 70 years of age, including patients from UCSF and other institutions showing symptoms consistent with PSP, as well as autopsy-confirmed PSP cases. Researchers compared biomarkers from these individuals to those from healthy controls and patients with other types of FTD. They observed generally lower protein levels in those with confirmed or suspected PSP compared to healthy study participants. The protein profile in autopsy-confirmed PSP cases also varied distinctly from those with other FTD forms and living patients. Notably, all individuals with confirmed or suspected PSP exhibited elevated levels of proteins linked to neurodegeneration. Additionally, certain inflammatory proteins were identified that correlated with disease severity, alongside a decrease in proteins vital for various brain cell functions, offering potential targets for future therapeutic interventions.

“This work aims to create a framework for using these newly identified proteins in future clinical trials,” said first author, Amy Wise, formerly of the UCSF Department of Neurology, and the Memory and Aging Center, and currently a medical student at UC Davis. “We hope to reach a point where a single biomarker, or a panel of biomarkers from a blood test or lumbar puncture, can provide definitive diagnostic and prognostic results for PSP.”

Related Links:
UCSF Department of Neurology

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.